Cargando…
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122276/ https://www.ncbi.nlm.nih.gov/pubmed/37087449 http://dx.doi.org/10.1186/s13195-023-01230-9 |
| _version_ | 1785029459898793984 |
|---|---|
| author | Dubois, Bruno López‑Arrieta, Jesús Lipschitz, Stanley Doskas, Triantafyllos Spiru, Luiza Moroz, Svitlana Venger, Olena Vermersch, Patrick Moussy, Alain Mansfield, Colin D. Hermine, Olivier Tsolaki, Magda |
| author_facet | Dubois, Bruno López‑Arrieta, Jesús Lipschitz, Stanley Doskas, Triantafyllos Spiru, Luiza Moroz, Svitlana Venger, Olena Vermersch, Patrick Moussy, Alain Mansfield, Colin D. Hermine, Olivier Tsolaki, Magda |
| author_sort | Dubois, Bruno |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10122276 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101222762023-04-23 Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial Dubois, Bruno López‑Arrieta, Jesús Lipschitz, Stanley Doskas, Triantafyllos Spiru, Luiza Moroz, Svitlana Venger, Olena Vermersch, Patrick Moussy, Alain Mansfield, Colin D. Hermine, Olivier Tsolaki, Magda Alzheimers Res Ther Correction BioMed Central 2023-04-22 /pmc/articles/PMC10122276/ /pubmed/37087449 http://dx.doi.org/10.1186/s13195-023-01230-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Dubois, Bruno López‑Arrieta, Jesús Lipschitz, Stanley Doskas, Triantafyllos Spiru, Luiza Moroz, Svitlana Venger, Olena Vermersch, Patrick Moussy, Alain Mansfield, Colin D. Hermine, Olivier Tsolaki, Magda Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial |
| title | Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial |
| title_full | Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial |
| title_fullStr | Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial |
| title_full_unstemmed | Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial |
| title_short | Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial |
| title_sort | correction: masitinib for mild-to-moderate alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122276/ https://www.ncbi.nlm.nih.gov/pubmed/37087449 http://dx.doi.org/10.1186/s13195-023-01230-9 |
| work_keys_str_mv | AT duboisbruno correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT lopezarrietajesus correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT lipschitzstanley correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT doskastriantafyllos correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT spiruluiza correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT morozsvitlana correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT vengerolena correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT vermerschpatrick correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT moussyalain correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT mansfieldcolind correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT hermineolivier correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT tsolakimagda correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial |